Our results demonstrated that the diagnostic performance of HNF1A‐AS1 was significantly higher than that of ALP, indicate that serum HNF1A‐AS1 should be further evaluated as novel non‐invasive biomarkers for discriminating osteosarcoma from benign bone tumours or healthy individuals. This evidence concerns the gene HNF1A and osteosarcoma.